CEO Interview: Michael Moe On GSV Capital, A New Vehicle To Finance Growth Companies
GSV Capital Founder & CEO Michael Moe interviewed by OneMedRadio. GSV raised $50 million in an IPO in May 2011 to invest in emerging technology companies. Moe describes the background and…
FDA Approves SoundBite Hearing System That Attaches to Your Teeth
A couple years ago I remember when I first posted about the development of the product and it sounded a bit out there but here it is with FDA approval…
Why This Lawyer Won’t Sue Me
I spent the entire last weekend with an attorney, not a desirable circumstance for most physicians. However, I wasn’t being deposed or interrogated on cross examination. This was a rendezvous…
FDA Approvs for New Blood Thinner For Knee and Hip Replacements
The drug was not theirs though as it came from Bayer Healthcare who already markets the drug in other countries and the market name for rivaroxaban, the Bayer drug, under…
Welcome New Interns and Residents
Another July 1st arrives at the Medical Centers of America. Educated observers remark at the fresh neatly pressed white coats entering the hospital. At the same time these fresh young…
Before and After Regenerative Stem Cell Treatment in Mexico – A Patient Talks
This is interesting to listen to the man from Canada who traveled to Mexico for treatment and it’s pretty astounding when he talks about what he couldn’t do before and…
ACO’s and CMS
The Accountable Care Organization is really an accounting mechanism and may have little to do with quality of care, or improving outcomes. Commonly called, “ACO” in health care circles…
Pharma R & D Spending is Down
And that’s probably bad news. Here is Megan McArdle, writing in The Atlantic: For the first time ever last year, the global drug industry cut its R&D spending. The trend…
ePatient Dave is In The Room (video)
Some of us talk about the “elephant in the room’ which everyone knows about but ignores. We also may make the same mistake about the person across from you…
The Battle Over Avastin
The use of Avastin for breast cancer was addressed by the U.S. Food and Drug Administration this week. The outcome was devastating for Roche and an emotional one for many…
